JP2018522888A5 - - Google Patents

Download PDF

Info

Publication number
JP2018522888A5
JP2018522888A5 JP2018501345A JP2018501345A JP2018522888A5 JP 2018522888 A5 JP2018522888 A5 JP 2018522888A5 JP 2018501345 A JP2018501345 A JP 2018501345A JP 2018501345 A JP2018501345 A JP 2018501345A JP 2018522888 A5 JP2018522888 A5 JP 2018522888A5
Authority
JP
Japan
Prior art keywords
isolated polypeptide
seq
nos
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018501345A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522888A (ja
JP6807606B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/042862 external-priority patent/WO2017011837A2/en
Publication of JP2018522888A publication Critical patent/JP2018522888A/ja
Publication of JP2018522888A5 publication Critical patent/JP2018522888A5/ja
Application granted granted Critical
Publication of JP6807606B2 publication Critical patent/JP6807606B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018501345A 2015-07-16 2016-07-18 多価及び多重特異性ｄｒ５結合融合タンパク質 Active JP6807606B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562193309P 2015-07-16 2015-07-16
US62/193,309 2015-07-16
PCT/US2016/042862 WO2017011837A2 (en) 2015-07-16 2016-07-18 Multivalent and multispecific dr5-binding fusion proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020196358A Division JP7244938B2 (ja) 2015-07-16 2020-11-26 多価及び多重特異性ｄｒ５結合融合タンパク質

Publications (3)

Publication Number Publication Date
JP2018522888A JP2018522888A (ja) 2018-08-16
JP2018522888A5 true JP2018522888A5 (enExample) 2019-07-04
JP6807606B2 JP6807606B2 (ja) 2021-01-06

Family

ID=57757772

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018501345A Active JP6807606B2 (ja) 2015-07-16 2016-07-18 多価及び多重特異性ｄｒ５結合融合タンパク質
JP2020196358A Active JP7244938B2 (ja) 2015-07-16 2020-11-26 多価及び多重特異性ｄｒ５結合融合タンパク質
JP2022191038A Pending JP2023022214A (ja) 2015-07-16 2022-11-30 多価及び多重特異性ｄｒ５結合融合タンパク質
JP2025032594A Pending JP2025084923A (ja) 2015-07-16 2025-03-03 多価及び多重特異性ｄｒ５結合融合タンパク質

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020196358A Active JP7244938B2 (ja) 2015-07-16 2020-11-26 多価及び多重特異性ｄｒ５結合融合タンパク質
JP2022191038A Pending JP2023022214A (ja) 2015-07-16 2022-11-30 多価及び多重特異性ｄｒ５結合融合タンパク質
JP2025032594A Pending JP2025084923A (ja) 2015-07-16 2025-03-03 多価及び多重特異性ｄｒ５結合融合タンパク質

Country Status (25)

Country Link
US (4) US10308720B2 (enExample)
EP (2) EP3322734B1 (enExample)
JP (4) JP6807606B2 (enExample)
KR (2) KR102760380B1 (enExample)
CN (2) CN114106178A (enExample)
AU (3) AU2016291701B2 (enExample)
CA (2) CA3288875A1 (enExample)
CY (1) CY1123615T1 (enExample)
DK (1) DK3322734T3 (enExample)
ES (1) ES2833773T3 (enExample)
HR (1) HRP20201785T1 (enExample)
HU (1) HUE051896T2 (enExample)
IL (3) IL307994A (enExample)
LT (1) LT3322734T (enExample)
MX (2) MX2018000523A (enExample)
NZ (1) NZ777930A (enExample)
PL (1) PL3322734T3 (enExample)
PT (1) PT3322734T (enExample)
RS (1) RS61062B1 (enExample)
RU (2) RU2748620C2 (enExample)
SG (1) SG10201912410TA (enExample)
SI (1) SI3322734T1 (enExample)
SM (1) SMT202100066T1 (enExample)
WO (1) WO2017011837A2 (enExample)
ZA (1) ZA201800238B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018191438A1 (en) 2017-04-11 2018-10-18 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
CN111819198A (zh) * 2017-12-28 2020-10-23 尤利乌斯·马克西米利安维尔茨堡大学 具有非FcγR依赖性激动活性的肿瘤坏死因子(TNF)受体超家族(TNFRSF)受体-激活抗体融合蛋白(具有非FcγR依赖性激动活性的TNFRSF受体-激活抗体融合蛋白；TRAAFFIAA)
CN110305210B (zh) * 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
IL277863B2 (en) 2018-04-11 2026-02-01 Inhibrx Inc Multispecific polypeptide constructs with forced CD3 binding and related methods and uses
WO2020047705A1 (zh) * 2018-09-03 2020-03-12 安菲尼生命科技有限公司 Dr5单域抗体及其用途
GB201903767D0 (en) * 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
BR112022006364A2 (pt) * 2019-10-01 2022-06-28 Epsilogen Ltd Anticorpo híbrido
CN115698088A (zh) * 2020-06-30 2023-02-03 和铂医药(上海)有限责任公司 免疫细胞衔接器多特异性结合蛋白及其制备和应用
WO2022002033A1 (zh) * 2020-06-30 2022-01-06 和铂医药(上海)有限责任公司 具有H2L2与HCAb结构的结合蛋白
CN115667316A (zh) * 2020-06-30 2023-01-31 和铂医药(上海)有限责任公司 Fab-HCAb结构的结合蛋白
IL305265A (en) * 2021-02-19 2023-10-01 Inhibrx Inc Preparations of DR5-binding polypeptides
CN119365489A (zh) * 2022-04-08 2025-01-24 印希比生物科学有限公司 Dr5激动剂与plk1抑制剂或cdk抑制剂组合疗法
CA3254393A1 (en) * 2022-05-23 2023-11-30 Inhibrx Biosciences, Inc. DR5 AGONIST AND IAP ANTAGONIST POLYTHERAPY
JP2025534309A (ja) 2022-09-28 2025-10-15 ヴァリンク セラピューティクス リミテッド 多価タンパク質およびスクリーニング法
KR20260032566A (ko) * 2023-06-29 2026-03-09 오디세이 테라퓨틱스, 인코포레이티드 항-trailr2 항원-결합 단백질 및 그의 용도

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69131017T2 (de) 1990-12-20 1999-07-15 Ixsys, Inc., San Diego, Calif. Optimierung von bindenden proteinen
US20020147140A1 (en) * 2000-01-31 2002-10-10 Rosen Craig A. Nucleic acids, proteins, and antibodies
KR20070010046A (ko) * 2004-04-06 2007-01-19 제넨테크, 인크. Ｄｒ5 항체 및 그의 용도
EA200701211A1 (ru) 2004-12-31 2007-12-28 Дженентек, Инк. Полипептиды, которые связываются с br3, и их применение
MX2007010349A (es) 2005-02-24 2008-04-09 Cemines Inc Composiciones y metodos para clasificar muestras biologicas.
CA2619725C (en) 2005-08-18 2016-06-07 Ramot At Tel Aviv University Ltd. Single chain antibodies against beta-amyloid peptide
TW200804425A (en) 2005-12-06 2008-01-16 Domantis Ltd Ligands that have binding specificity for EGFR and/or VEGF and methods of use therefor
DK1987178T3 (en) 2006-02-20 2015-04-20 Phylogica Ltd Process for the construction and screening of peptide structure libraries
JP2008133206A (ja) 2006-11-28 2008-06-12 Yokohama City Univ 緑膿菌に対して感染防御能を誘導できる医薬組成物
SG186017A1 (en) 2007-11-30 2012-12-28 Kalobios Pharmaceuticals Inc Antibodies to the pcrv antigen of pseudomonas aeruginosa
HUE042053T2 (hu) 2008-06-05 2019-06-28 Ablynx Nv Vírus burokfehérjéi elleni aminosav-szekvenciák és az azokat tartalmazó polipeptidek virális betegségek kezelésére
EP2328929A2 (en) * 2008-09-10 2011-06-08 Bac Ip B.V. Antigen-binding proteins that inhibit superantigens for the treatment of skin diseases
US9096659B2 (en) 2009-03-18 2015-08-04 Wake Forest University Health Sciences Flagellin fusion proteins and use thereof to induce immune responses against Pseudomonas aeruginosa
US20100281003A1 (en) 2009-04-02 2010-11-04 New York University System and uses for generating databases of protein secondary structures involved in inter-chain protein interactions
CN101717775B (zh) * 2009-11-13 2012-01-04 厦门大学 抗人死亡受体5的单链抗体基因
HRP20251657T1 (hr) 2009-12-14 2026-02-13 Ablynx N.V. Imunoglobulinska protutijela s jednostrukom varijabilnom domenom protiv ox40l, konstrukti i njihova terapijska upotreba
US9120855B2 (en) * 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
WO2011134060A1 (en) 2010-04-27 2011-11-03 National Research Council Of Canada Anti-icam-1 single domain antibody and uses thereof
NZ607473A (en) 2010-09-27 2014-11-28 Morphosys Ag Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl
US9771416B2 (en) 2010-10-25 2017-09-26 National Research Council Of Canada Clostridium difficile-specific antibodies and uses thereof
KR20130133212A (ko) 2010-12-23 2013-12-06 인터셀 오스트리아 아게 입원 및 다른 환자에서 OprF/I 물질 및 이의 용도
PE20141522A1 (es) 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
SMT202000091T1 (it) * 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
ES2749349T3 (es) 2011-11-07 2020-03-19 Medimmune Llc Proteínas de unión multiespecíficas y multivalentes y usos de las mismas
JP6170940B2 (ja) 2011-12-20 2017-07-26 アダエラータ、リミテッド パートナーシップＡｄａｅｒａｔａ， Ｌｉｍｉｔｅｄ Ｐａｒｔｎｅｒｓｈｉｐ Ｐｃｓｋ９の阻害剤としての単一ドメイン抗体
MX2014010495A (es) 2012-03-02 2014-11-14 Ablynx Nv Polipeptidos que enlazan a pcrv.
WO2013167883A1 (en) 2012-05-07 2013-11-14 The University Court Of The University Of Aberdeen Single domain binding molecule
EP2684896A1 (en) * 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
US20140161796A1 (en) 2012-09-13 2014-06-12 Andreas Loew Single chain proteins with c-terminal modifications
JP2015535005A (ja) 2012-11-06 2015-12-07 メディミューン，エルエルシー 抗シュードモナス属（Ｐｓｅｕｄｏｍｏｎａｓ）ＰｓｌおよびＰｃｒＶ結合分子を用いた併用治療
CN102924600B (zh) * 2012-11-14 2013-10-30 河南大学 死亡受体5激动性多价抗体及其在制备抗肿瘤药物中的应用
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
US9862777B2 (en) 2013-05-28 2018-01-09 Vib Vzw Single domain antibodies against SOD1 and their use in medicine
CA2936053A1 (en) * 2014-01-10 2015-07-16 Teikyo Heisei University Recombinant obligate anaerobic gram-positive bacteria

Similar Documents

Publication Publication Date Title
RU2021111382A (ru) Мультивалентные и мультиспецифические гибридные белки, связывающиеся с dr5
JP2020508655A5 (enExample)
JP2022512684A5 (enExample)
JP2019116474A5 (enExample)
JP2021503455A5 (enExample)
JP2020525032A5 (enExample)
JP2022512132A5 (enExample)
JP2021508469A5 (enExample)
JP2023551027A5 (enExample)
JP2019527553A5 (enExample)
JP2017504578A5 (enExample)
JP2018523493A5 (enExample)
JP2019532619A5 (enExample)
JP2010502183A5 (enExample)
JP2018520993A5 (enExample)
JP2021520832A5 (enExample)
JP2009225799A5 (enExample)
EP3625249A1 (en) Method of preparing ph-dependent antibodies
RU2018106452A (ru) Поливалетные и полиспецифичные gitr-связывающие слитые белки
RU2019121086A (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
JP2012501670A5 (enExample)
JP2018526981A5 (enExample)
JP2013506428A5 (enExample)
JP2022545647A5 (enExample)
JP2012525829A5 (enExample)